薬物スクリーニングの市場規模、シェア、動向分析レポート：製品タイプ別、サンプルタイプ別、最終用途別、地域別、セグメント別予測、2024年～2030年

薬物スクリーニング市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の薬物スクリーニング市場規模は2030年までに119億9,000万米ドルに達すると予測され、予測期間中にCAGR 4.0％で成長しています。

この市場を牽引しているのは、職場の安全に対する懸念の高まり、規制への対応、検査方法の技術的進歩に後押しされた薬物乱用の正確な検出要件です。

イングランドで薬物・アルコールサービスに接触している成人の数は、2020年～2021年の275,896人から2021年～2022年には289,215人へと4.8％増加しており、これは同国における薬物乱用の蔓延が拡大していることを示しています。薬物乱用の有病率の上昇は、エビデンスに基づく治療オプションへのアクセス拡大や、薬物・アルコール乱用のリスクに関する認識を高める公衆衛生キャンペーンなど、効果的な予防・治療戦略の必要性をさらに後押ししています。

同様に、2020年の12歳以上の米国人における違法薬物使用の罹患率は約3,731万人で、この数年間で前年比3.8%の増加を示しており、この罹患率の増加は市場の重要な促進要因となっています。この増加は、職場、学校、ヘルスケア環境における包括的な薬物スクリーニング・プログラムの緊急の必要性を浮き彫りにし、安全性、規制の遵守、薬物乱用に悩む人々への適切なケアとサポートの提供を確実にします。

さらに、新製品の発売、合併、買収などの市場プレイヤーのイニシアチブが市場成長に寄与しています。例えば、2024年2月、ニューヨークの大手薬物検査プロバイダーであるMobile Health社は、雇用者向けに迅速な薬物検査を導入し、1時間以内に結果が出るようにしました。精度と汎用性の高い尿ベースの検査に焦点を当てたこの技術革新は、採用プロセスを前進させ、ニューヨークの人材獲得に革命をもたらしました。さらに、2023年12月には、遺伝子マーカーを通じて個人のオピオイド使用障害発症リスクを評価するAvertD検査がFDAに承認され、オピオイド危機との闘いにおける重要な技術革新となります。AutoGenomics社が開発したこの検査は、患者が初めて経口オピオイド鎮痛薬にさらされる前、特に外科手術を予定している患者に使用するよう設計されています。この検査は、患者やヘルスケアプロバイダーがオピオイドの使用について十分な情報を得た上で意思決定を行い、中毒や誤用のリスクを低減することを目的としています。

AvertDの承認は、2022年8月のFDA過剰摂取防止フレームワークのイントロダクション、2023年3月と7月の非処方用ナロキソン点鼻薬の承認など、オピオイド危機に対するFDAの広範な取り組みの一環です。こうした危機への対処に対するFDAのコミットメントは、オピオイド使用障害のリスクの評価と軽減に役立つ医療機器の開発に対する継続的な支援にも表れています。

薬物スクリーニング市場レポートハイライト

• 製品タイプ別では消耗品が2023年に最も速い収益で市場シェアを占め、主要企業がキット開発のために行っている広範な研究開発イニシアチブのため、予測期間中に最も速い成長率で成長すると予測されます。
• タイプ別では、尿サンプルが2023年に最大の収益シェアを占め、市場を独占しました。尿による薬物検査は、毛髪検査などの他の検査方法に比べて一般的に費用対効果が高いです。
• 薬物治療センターの最終用途分野が2023年に市場を独占したが、これは薬物乱用治療とリハビリテーションへの注目が高まり、これらのセンターにおける薬物検査サービスの需要が高まっていることに起因しています。
• 北米は、先進的なヘルスケアインフラ、違法薬物の消費量の多さ、職場での薬物検査の必要性などの要因により、世界市場を独占しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 薬物スクリーニング市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 薬物スクリーニング市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析

第4章 薬物スクリーニング市場：製品タイプの推定・動向分析

• 世界の薬物スクリーニング市場：製品タイプダッシュボード
• 世界の薬物スクリーニング市場：製品タイプの変動分析
• 世界の薬物スクリーニング市場：製品タイプ、収益別
• 機器
• 迅速検査装置
• 消耗品
• サービスおよびその他

第5章 薬物スクリーニング市場：技術推定・動向分析

• 世界の薬物スクリーニング市場：サンプルタイプダッシュボード
• 世界の薬物スクリーニング市場：サンプルタイプの変動分析
• 世界の薬物スクリーニング市場：サンプルタイプ別、収益別
• 尿サンプル
• 呼気サンプル
• 口腔液サンプル
• 毛髪サンプル
• その他のサンプル

第6章 薬物スクリーニング市場：最終用途の推定・動向分析

• 世界の薬物スクリーニング市場：最終用途ダッシュボード
• 世界の薬物スクリーニング市場：最終用途変動分析
• 世界の薬物スクリーニング市場：最終用途別、収益別
• 病院
• 刑事司法および法執行機関
• 職場
• 薬物治療センター
• 個人ユーザー
• 疼痛管理センター
• 学校と大学
• その他

第7章 薬物スクリーニング市場：製品タイプ、サンプルタイプ、最終用途別の地域推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主なディストリビューターとチャネルパートナーのリスト
  • 主要顧客
  • 主要市場の企業シェア分析, 2023年
  • Abbott
  • Quest Diagnostics Incorporated
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Siemens Healthcare AG
  • Laboratory Corporation of America Holdings
  • Alfa Scientific Designs, Inc.,
  • OraSure Technologies, Inc.
  • Omega Laboratories, Inc.
  • Dragerwerk AG &Co. KGaA
  • Bio-Rad Laboratories, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America drug screening market, by region, 2018 - 2030 (USD Million)
• Table 3 North America drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 4 North America drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 5 North America drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 6 U.S. drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 7 U.S. drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 8 U.S. drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 9 Canada drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 10 Canada drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 11 Canada drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 12 Mexico drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 13 Mexico drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 14 Mexico drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 15 Europe drug screening market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 17 Europe drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 18 Europe drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 19 UK drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 20 UK drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 21 UK drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 22 Germany drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 23 Germany drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 24 Germany drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 25 France drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 26 France drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 27 France drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 28 Italy drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 29 Italy drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 30 Italy drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 31 Spain drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 32 Spain drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 33 Spain drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 34 Denmark drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 35 Denmark drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 36 Denmark drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 37 Sweden drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 38 Sweden drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 39 Sweden drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 40 Norway drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 41 Norway drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 42 Norway drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific drug screening market, by region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 46 Aisa Pacific drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 47 Japan drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 48 Japan drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 49 Japan drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 50 China drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 51 China drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 52 China drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 53 India drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 54 India drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 55 India drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 56 Australia drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 57 Australia drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 58 Australia drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 59 South Korea drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 60 South Korea drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 61 South Korea drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 62 Thailand drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 63 Thailand drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 64 Thailand drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 65 Latin America drug screening market, by region, 2018 - 2030 (USD Million)
• Table 66 Latin America drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 67 Latin America drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 68 Latin America drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 69 Brazil drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 70 Brazil drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 71 Brazil drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 72 Argentina drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 73 Argentina drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 74 Argentina drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 75 MEA drug screening market, by region, 2018 - 2030 (USD Million)
• Table 76 MEA drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 77 MEA drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 78 MEA drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 79 South Africa drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 80 South Africa drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 81 South Africa drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 85 UAE drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 86 UAE drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 87 UAE drug screening market, by end-use, 2018 - 2030 (USD Million)
• Table 88 Kuwait drug screening market, by product type, 2018 - 2030 (USD Million)
• Table 89 Kuwait drug screening market, by sample type, 2018 - 2030 (USD Million)
• Table 90 Kuwait drug screening market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Drug screening market: market outlook
• Fig. 14 Drug screening competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Drug screening market driver impact
• Fig. 18 Drug screening market restraint impact
• Fig. 19 Drug screening market: Product type movement analysis
• Fig. 20 Drug screening market: Product type outlook and key takeaways
• Fig. 21 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Immunoassays analyzers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Chromatography instruments market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Breath analyzers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Fuel cell breath analyzers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Semi-conductor breath analyzers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Others breath analyzers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Rapid testing devices estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Urine testing devices estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Drug testing cups estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Dip cards estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Drug testing cassettes estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Oral fluid testing devices estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Consumables estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Assay kits estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Sample collection devices estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Calibrators & controls estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Other consumables estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Services and others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Drug screening market: Sample type movement analysis
• Fig. 41 Drug screening market: Sample type outlook and key takeaways
• Fig. 42 Urine samples market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Breath samples estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Oral fluid samples market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 45 Hair samples estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Other samples estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Drug screening market: End-use movement analysis
• Fig. 48 Drug screening market: End-use outlook and key takeaways
• Fig. 49 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 Criminal justice and law enforcement agencies estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 Workplaces market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 Drug treatment centers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 Individual users market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 54 Pain management centers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 55 Schools & colleges market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 56 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 57 Global drug screening market: Regional movement analysis
• Fig. 58 Global drug screening market: Regional outlook and key takeaways
• Fig. 59 Global drug screening market share and leading players
• Fig. 60 North America, by country
• Fig. 61 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 U.S. key country dynamics
• Fig. 63 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Canada key country dynamics
• Fig. 65 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Mexico key country dynamics
• Fig. 67 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 UK key country dynamics
• Fig. 70 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Germany key country dynamics
• Fig. 72 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 France key country dynamics
• Fig. 74 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Italy key country dynamics
• Fig. 76 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Spain key country dynamics
• Fig. 78 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Denmark key country dynamics
• Fig. 80 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Sweden key country dynamics
• Fig. 82 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Norway key country dynamics
• Fig. 84 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Japan key country dynamics
• Fig. 87 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 China key country dynamics
• Fig. 89 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 India key country dynamics
• Fig. 91 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Australia key country dynamics
• Fig. 93 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 South Korea key country dynamics
• Fig. 95 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 96 Thailand key country dynamics
• Fig. 97 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 99 Brazil key country dynamics
• Fig. 100 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 101 Argentina key country dynamics
• Fig. 102 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 103 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 104 South Africa key country dynamics
• Fig. 105 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 106 Saudi Arabia key country dynamics
• Fig. 107 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 108 UAE key country dynamics
• Fig. 109 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 110 Kuwait key country dynamics
• Fig. 111 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 112 Market share of key market players- Global drug screening market

Drug Screening Market Growth & Trends:

The global drug screening market size is anticipated to reach USD 11.99 billion by 2030 and is growing at a CAGR of 4.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by increasing workplace safety concerns, regulatory compliance, and requirement for accurate detection of substance abuse, aided by technological advancements in testing methods.

The increase in number of adults in contact with drug and alcohol services in England has increased from 275,896 in 2020 - 2021¬ to 289,215 in 2021 - 2022, representing a 4.8% rise, which signifies a growing prevalence of substance abuse in the country. The rising prevalence of substance abuse further propels the need for effective prevention and treatment strategies, including the expansion of access to evidence-based treatment options and public health campaigns to raise awareness about the risks of drug and alcohol misuse.

Similarly, the incidence of illegal substance use among Americans aged 12 and older in 2020 was around 37.31 million, and shows a 3.8% year-over-year increase over the years; this rising prevalence serves as a significant driver for the market. This increase highlights the urgent need for comprehensive drug screening programs in workplaces, schools, and healthcare settings to ensure safety, compliance with regulations, and provision of appropriate care and support for individuals struggling with substance abuse.

Furthermore, initiatives by market players such as new product launches, mergers, acquisitions, and others contribute to market growth. For instance, in February 2024, Mobile Health, the leading drug testing provider in NYC, introduced rapid drug testing for employers, ensuring results in an hour or less. With a focus on urine-based testing for accuracy and versatility, this innovation advances the hiring process, revolutionizing talent acquisition in NYC. In addition, in December 2023, the FDA's approval of the AvertD test, which assesses an individual's risk of developing opioid use disorder through genetic markers, marks a significant innovation in the fight against the opioid crisis. This test, developed by AutoGenomics, Inc., is designed to be used before a patient is first exposed to oral opioid pain medications, particularly in patients scheduled for surgical procedures. The test is intended to help patients and healthcare providers make informed decisions about opioid use, potentially reducing the risk of addiction and misuse.

The approval of AvertD is part of FDA's broader efforts to address opioid crisis, which includes the introduction of FDA Overdose Prevention Framework in August 2022 and the approval of nonprescription naloxone nasal spray products in March and July 2023. The FDA's commitment to addressing these crisis is evident in its continued support for the development of medical devices that can help assess and mitigate the risk of opioid use disorder.

Drug Screening Market Report Highlights:

• Consumables dominated the product type segment with the fastest revenue market share in 2023 and is anticipated to grow at fastest growth rate over the forecast period owing to extensive R&D initiatives undertaken by major players to develop kits
• Based on type segment, urine sample dominated the market with the largest revenue share in 2023 attributed to the ease of collection. Urine drug testing is generally more cost-effective compared to other testing methods, such as hair testing
• Drug treatment centers end-use segment dominated the market in 2023, attributed to the increasing focus on substance abuse treatment and rehabilitation, leading to a higher demand for drug testing services in these centers
• North America dominated the global market owing to factors such as advanced healthcare infrastructure, the region's high consumption of illegal substances, and the necessity for workplace drug tests

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Sample Type
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product type outlook
  • 2.2.2. Sample type outlook
  • 2.2.3. End-use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Drug Screening Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing drug and alcohol consumption
    • 3.2.1.2. Growing demand for drug screening measures
    • 3.2.1.3. Rise in government funding
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Rising false positive and negative results in drug screeni9ng limits screening process
    • 3.2.2.2. Rise in privacy concerns limiting the expansion of drug screening practices
• 3.3. Drug Screening Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Drug Screening Market: Product Type Estimates & Trend Analysis

• 4.1. Global Drug Screening Market: Product Type Dashboard
• 4.2. Global Drug Screening Market: Product Type Movement Analysis
• 4.3. Global Drug Screening Market by Product Type, Revenue
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. Immunoassays Analyzers
    • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.3. Chromatography Instruments
    • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.4. Breath Analyzer
    • 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4.2. Fuel Cell Breath Analyzer
    • 4.4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4.3. Semi-conductor Breath Analyzer
    • 4.4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4.4. Others Breath Analyzer
    • 4.4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Rapid Testing Devices
  • 4.5.1. Rapid testing devices market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.2. Urine Testing Devices
    • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.2. Drug Testing Cups
    • 4.5.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.3. Dip Cards
    • 4.5.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.4. Drug Testing Cassettes
    • 4.5.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.3. Oral Fluid Testing Devices
    • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Consumables
  • 4.6.1. Consumables market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.2. Assay Kits
    • 4.6.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.3. Sample Collection Devices
    • 4.6.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.4. Calibrators & Controls
    • 4.6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.5. Other Consumables
    • 4.6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Services and Others
  • 4.7.1. Services and others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Drug Screening Market: Technology Estimates & Trend Analysis

• 5.1. Global Drug Screening Market: Sample Type Dashboard
• 5.2. Global Drug Screening Market: Sample Type Movement Analysis
• 5.3. Global Drug Screening Market by Sample Type, Revenue
• 5.4. Urine Samples
  • 5.4.1. Urine samples market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Breath Samples
  • 5.5.1. Breath samples market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Oral Fluid Samples
  • 5.6.1. Oral fluid samples market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Hair Samples
  • 5.7.1. Hair samples market estimates and forecasts 2018 - 2030 (USD Million)
• 5.8. Other Samples
  • 5.8.1. Other samples market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Drug Screening Market: End-use Estimates & Trend Analysis

• 6.1. Global Drug Screening Market: End-use Dashboard
• 6.2. Global Drug Screening Market: End-use Movement Analysis
• 6.3. Global Drug Screening Market by End-use, Revenue
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Criminal Justice & Law Enforcement Agencies
  • 6.5.1. Clinical laboratories market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Workplaces
  • 6.6.1. Workplaces market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. Drug Treatment Centers
  • 6.7.1. Drug treatment centers market estimates and forecasts 2018 - 2030 (USD Million)
• 6.8. Individual Users
  • 6.8.1. Individual users market estimates and forecasts 2018 - 2030 (USD Million)
• 6.9. Pain Management Centers
  • 6.9.1. Pain management centers market estimates and forecasts 2018 - 2030 (USD Million)
• 6.10. Schools & Colleges
  • 6.10.1. Schools & Colleges market estimates and forecasts 2018 - 2030 (USD Million)
• 6.11. Others
  • 6.11.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Drug Screening Market: Regional Estimates & Trend Analysis by Product Type, Sample Type, and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.6. Denmark
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.8. Norway
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Abbott
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Quest Diagnostics Incorporated
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. F. Hoffmann-La Roche Ltd
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Thermo Fisher Scientific Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Siemens Healthcare AG
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Laboratory Corporation of America Holdings
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Alfa Scientific Designs, Inc.,
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. OraSure Technologies, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Omega Laboratories, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Dragerwerk AG & Co. KGaA
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Bio-Rad Laboratories, Inc.
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives